BriaCell Therapeutics Corp.
NASDAQ:BCTX
0.39 (USD) • At close January 14, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.083 | 0.016 | 0.015 | 0.016 | 0.014 | 0.014 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| -0.083 | -0.016 | -0.015 | -0.016 | -0.014 | -0.014 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 26.752 | 15.337 | 8.021 | 1.315 | 2.221 | 3.74 | 2.389 | 1.706 | 0.723 | 0.106 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 6.152 | 7.936 | 7.267 | -3.675 | -1.371 | -0.932 | -1.052 | 0.876 | 0.942 | 1.334 | 0.436 | 0.424 | 0.556 | 1.051 | 0.323 | 0.204 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| -0.179 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 5.973 | 7.936 | 7.267 | -3.675 | -1.371 | -0.932 | -1.052 | 0.876 | 0.942 | 1.334 | 0.436 | 0.424 | 0.556 | 1.051 | 0.323 | 0.204 | 0.114 | 0.129 | 0.009 |
| Other Expenses
| 0 | 0 | -15.292 | -1.331 | -2.235 | -3.754 | -0.313 | 0 | 0.002 | 0.001 | 0.001 | 0 | -0.004 | 0.002 | 0.001 | 0.002 | 0 | 0 | 0 |
| Operating Expenses
| 32.726 | 23.272 | -0.003 | -3.69 | -1.385 | -0.946 | -1.065 | 2.582 | 1.667 | 1.44 | 0.437 | 0.424 | 0.552 | 1.053 | 0.325 | 0.234 | 0.114 | 0.129 | 0.009 |
| Operating Income
| -32.808 | -23.272 | -15.289 | 3.69 | 1.385 | 0.946 | -3.819 | -2.582 | -1.667 | -1.44 | -0.437 | -0.424 | -1.198 | -1.053 | -0.325 | -0.234 | -0.114 | -0.129 | -0.009 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 28.017 | 2.97 | 3.739 | -6.843 | -0.085 | 0 | -1.593 | 0.634 | 0.482 | -1.241 | -7.709 | 0.056 | 0.203 | -0.037 | -0.595 | 0.003 | 0 | 0 | 0 |
| Income Before Tax
| -4.791 | -20.302 | -11.55 | 3.69 | 1.385 | 0.946 | 1.065 | -2.584 | -1.696 | -2.682 | -8.146 | -0.369 | -0.996 | -1.09 | -0.92 | -0.231 | 0 | 0 | 0 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.063 | -0.153 | 0.031 | 6.584 | -0.072 | 0.344 | 1.593 | 0.639 | 0.548 | 2.048 | 8.45 | -0.044 | -0.201 | -0.024 | 0.601 | 0.012 | -0.013 | -0.005 | 0.001 |
| Net Income
| -4.791 | -20.302 | -11.581 | -2.895 | 1.385 | 0.603 | 1.065 | -2.584 | -1.696 | -2.682 | -8.146 | -0.369 | -0.996 | -1.079 | -0.901 | -0.229 | -0.099 | -0.116 | -0.009 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.29 | -1.3 | -0.75 | -0.64 | 1.94 | 1.04 | 2.49 | -7.61 | -5.88 | -10.76 | -138.07 | -6.25 | -16.93 | -33.02 | -49.58 | -25.62 | -20.45 | -27.92 | -4.18 |
| EPS Diluted
| -0.29 | -1.3 | -0.75 | -0.64 | 1.94 | 1.04 | 2.49 | -7.32 | -5.88 | -10.76 | -138.07 | -6.25 | -16.93 | -33.02 | -49.58 | -25.62 | -20.45 | -27.92 | -4.18 |
| EBITDA
| -4.772 | -30.666 | -15.134 | -8.687 | -3.965 | -6.675 | -4.96 | -3.218 | -2.176 | -1.798 | -0.003 | -0.463 | -0.068 | -1.012 | 0.256 | -0.234 | -0.114 | -0.129 | -0.009 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |